The U.S. Supreme Court made it easier for shareholders to press class action securities-fraud suits, ruling that Amgen Inc. must defend against claims that it misled investors about the safety of two drugs for anemia.
The justices, voting 6-3, today said investors can sue as a group without having to first show that misinformation propped up a company’s stock price.
‘Enforcement 40’ for 2020
Join Us On LinkedIn
Join the Securities Litigation and Enforcement Group on LinkedIn